Bayer presents positive third quarter financial results

13 November 2018

Germany’s Bayer (BAYN: DE) has provided an upbeat third quarter financial results statement, showing sales of pharmaceuticals rose by 4.8% to 4.2 billion euros ($4.7 billion).

Overall revenues for the group, including the firm’s animal health and crop science divisions, rose 1.9% to 9.9 billion euros ($11.1 billion). Net income was 2.9 billion euros, a 25% drop from the same period last year, or 2.94 euros per share. Bayer’s shares rose an initial 2.7% this morning.

Sales of Bayer’s key growth products amounted to 1.7 billion euros, which translates into combined growth of 15.7% for the oral anticoagulant Xarelto (rivaroxaban), the eye medicine Eylea (aflibercept), the cancer drugs Xofigo (radium-223) and Stivarga (regorafenib), and the pulmonary hypertension treatment Adempas (riociguat).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK